Pain Management

Although there were some differences in response after dosing, both OTC and oral prescriptions demonstrated statistically significant improvements in pain.

Filling a prescription for a controlled substance requires more oversight than the average prescription.

Zavegepant joins other CGRP antagonists as an option for individuals experiencing migraine.

The alert was implemented after passage of a state senate bill.

Study results add to the body of evidence demonstrating the efficacy of CGRP inhibitors for migraine treatment and prophylaxis.

This treatment is the first and only long-acting buprenorphine injectable with weekly and monthly doses.

A new meta-analysis found duloxetine to be the only commonly prescribed medication that was effective.

Only the 60 mg dose of atogepant is approved for chronic migraine prevention.

A new study from JAPHA explores the link between OUD and social factors.

Naloxone hydrochloride nasal spray (Narcan) 4 mg is expected to be available over the counter in late summer 2023.

Vitamin D supplementation may be an effective and safe adjunctive prophylactic therapy to topiramate for children who experience migraine attacks, showed a study conducted in Saudi Arabia.

The test is intended to complement the company’s TBI plasma test, which received FDA clearance in 2021.

Nerivio received clearance in January 2021 for use in acute migraine.

The letter outlined 7 steps that the Biden administration can take without the need for additional legislation.

The number of digital therapeutics available for migraine is likely to expand.

Long, hot showers and cold, dry air can contribute to psoriasis flare-ups during the winter months.

New legislation removes what many perceived as a barrier to treating opioid use disorder.

The PDUFA date has been set for May 22, 2023.

Women on Medicaid with opioid use disorder (OUD) who use medications for opioid use disorder (MOUD) are more likely to use contraception and to undergo female sterilization than peers not prescribed MOUD.

Patients are finding relief in alternative therapies for this chronic skin disease.

Take a look back at our most popular pain management coverage for 2022.

Biosimilar medications stand to significantly increase cost savings for patients.

New pathways of care are needed to improve health care spending.

Haylea Hannah, MSPH, PhD, discusses her research on the barriers to medications for opioid use disorder that people who are incarcerated can face and what pharmacists can do to address the barriers.